Epidemiology of Venous Thrombosis and Pulmonary Embolism

静脉血栓栓塞症(VTE)，包括深静脉血栓形成和肺栓塞，是一种主要的 美国发病率和死亡率的贡献者。我们建议纵向续签3年 血栓栓塞症病因学研究--静脉血栓栓塞症在中国动脉粥样硬化风险中的前瞻性研究 社区(ARIC)研究和心血管健康研究(CHS)队列，涉及21,680名参与者 随后的二十多年里。在前四个项目期内，共发生了1,055次VTE， 我们通过91篇出版物成功地确定或澄清了静脉血栓栓塞症的多种遗传和非遗传危险因素。 我们计划在此继续期间以这些发现为基础，通过增加VTE案例、解决新的 与VTE风险因素或结果相关的假设，并使用所有项目期间的信息来 提高对静脉血栓栓塞术发生的认识。 Lite续订的目标是：(1)将ARIC中的VTE事件跟踪再延长4年，增加 到262场小型VTE活动的数量，达到1,317场。(2)深入探讨导致较高收入水平的可能原因 非裔美国人的VTE发病率高于白人，并对临床相关种族进行系统测试 与静脉血栓栓塞症危险因素的相互作用。(3)检验事件VTE与小说的预期关联性 免费提供生物标志物：血浆半乳糖素3、性激素和血浆NT-2的变化 ProBNP、肌钙蛋白T和C反应蛋白。(4)测定血浆高分子激肽原和 前激肽释放酶是凝血接触途径的组成部分，并确定它们与VTE的相关性。(5) 测试VTE与加速衰老的血液生物标记物的前瞻性关联--较短的染色体 长度和较低的有丝分裂试验拷贝数。(6)研究VTE对身体健康的长期影响 功能和生活质量。 LITE是美国为数不多且最有成效的VTE前瞻性研究之一。续订3年将允许 Lite将提供有关VTE风险因素和结果的新信息，并可能对VTE产生影响 预防和治疗。

Venous thromboembolism (VTE), comprising deep venous thrombosis and pulmonary embolism, is a major contributor to morbidity and mortality in the U.S. We propose a 3-year renewal of the Longitudinal Investigation of Thromboembolism Etiology (LITE), a prospective study of VTE in the Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS) cohorts, involving 21,680 participants followed for more than two decades. In the previous four project periods, during which 1,055 VTEs occurred, we successfully identified or clarified, via 91 publications, multiple genetic and non-genetic risk factors for VTE. We plan to build upon these findings during this continuation, by adding VTE cases, addressing new hypotheses related to VTE risk factors or outcomes, and using the information from all project periods to improve understanding of VTE occurrence. LITE renewal aims are to: (1) Extend VTE event follow-up in ARIC for 4 more years, increasing the number of LITE VTE events by 262, to a total of 1,317. (2) Explore in depth possible reasons for the higher rates of VTE incidence in African Americans than whites, and systematically test for clinically relevant race interactions with risk factors for VTE. (3) Test the prospective association of incident VTE with novel biomarkers available at no additional cost: plasma galactin 3, sex hormones, and changes in plasma NT- proBNP, troponin T, and C-reactive protein. (4) Measure plasma high molecular weight kininogen and prekallikrein, components of the contact pathway of coagulation, and determine their association with VTE. (5) Test the prospective association of VTE with blood-based biomarkers of accelerated aging—shorter teleomere length and lower mitochontrial copy number. (6) Study the long-term consequences of VTE on physical functioning and quality of life. LITE is one of the few and most productive US prospective studies on VTE. A 3-year renewal will allow LITE to contribute new information on VTE risk factors and outcomes, with potential implications for VTE prevention and treatment.